Stocksigma LogoStocksigma Logo

Mankind Pharma Reports Robust Q2 FY27 Results with Strong Margin Expansion

Mankind Pharma reported Q2 FY27 revenue of INR 4,338 Cr, up 17.3% YoY, driven by a 14.8% increase in domestic business to INR 3,657 Cr and a 32.7% rise in

Mankind Pharma Reports Robust Q2 FY27 Results with Strong Margin Expansion

Mankind Pharma Ltd 路 Investor Presentation 路 26 Oct 2026, 8:58 pm

Mankind Pharma Reports Robust Q2 FY27 Results with Strong Margin Expansion Mankind Pharma reported Q2 FY27 revenue of INR 4,338 Cr, up 17.3% YoY, driven by a 14.8% increase in domestic business to INR 3,657 Cr and a 32.7% rise in exports to INR 681 Cr. EBITDA grew 27.2% YoY to INR 1,175 Cr as EBITDA margin expanded 210 bps to 27.1%. PAT surged 37.7% YoY to INR 716 Cr with a 16.5% margin. Net debt stood at INR 2,639 Cr (0.6x Adj. EBITDA). The company entered next-gen CAR-T therapies via an ACTx acquisition.

Original exchange filing (PDF)

More announcements from Mankind Pharma Ltd

All Mankind Pharma Ltd announcements